New hope for kidney cancer patients: drug combo targets tumors after immunotherapy fails
NCT ID NCT07165418
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 32 times
Summary
This study tests whether a combination of two drugs (vorolanib and everolimus) works better than the standard drug sunitinib for people with advanced kidney cancer that has gotten worse after immunotherapy. About 116 adults will be randomly assigned to one of the two treatments. The goal is to see which approach helps keep the cancer from growing longer and has fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.